May 22 (Reuters) - The U.S. Food and Drug Administration has approved British drugmaker GSK's (GSK.L), opens new tab asthma drug to treat some patients with a chronic lung disease commonly known ...

Eosinophils, which are a type of white blood cell, serve as a biomarker for type 2 inflammation and help determine the risk of COPD exacerbations, GSK explained in a release. COPD—which includes ...

GSK plans to seek approval of a new antibiotic for complicated urinary tract infections after the drug succeeded in a Phase 3 trial. An independent monitoring board recommended ending the study ...

GSK's Nucala is a monoclonal antibody that inhibits interleukin-5, which helps regulate eosinophils, a type of white blood cell that causes inflammation in the lungs when overproduced. The ...

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD). Nucala (mepolizumab) has ...

CAMBRIDGE, Mass. - Spero Therapeutics, Inc. (NASDAQ: SPRO) and GSK plc (LSE/NYSE: GSK) announced positive outcomes from their Phase 3 trial of tebipenem HBr, a potentially groundbreaking oral ...

GSK's Nucala is a monoclonal antibody that inhibits interleukin-5, which helps regulate eosinophils, a type of white blood cell that causes inflammation in the lungs when overproduced. The regulator ...

The FDA has approved GSK's gepotidacin, the first oral antibiotic to offer a new mechanism of action in uncomplicated urinary tract infections (uUTIs) in nearly 30 years, after a priority review.

GSK plans to include the data in a U.S. FDA filing in the second half of 2025, with full results to be presented at an upcoming scientific congress and published in a peer-reviewed journal.